The chemical class of Poliovirus Type 3 Inhibitors encompasses a variety of compounds that can potentially disrupt different stages of the Poliovirus Type 3 life cycle. This class includes antiviral agents like Pleconaril, which specifically target the viral capsid proteins, preventing uncoating and replication. Guanidine Hydrochloride and 2'-C-Methylcytidine are known to interfere with viral RNA replication processes, thus hindering the synthesis of viral genetic material.
Ribavirin, a broad-spectrum antiviral, has mechanisms that include the inhibition of RNA-dependent RNA polymerase, making it potentially effective against RNA viruses like Poliovirus Type 3. Enviroxime and Rupintrivir (AG7088) target specific proteins involved in viral RNA replication, further demonstrating the diversity of potential inhibition mechanisms. Chloroquine, although primarily an antimalarial drug, exhibits broad antiviral properties that might disrupt the required pH conditions for viral replication or entry.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Guanidine Hydrochloride | 50-01-1 | sc-202637 sc-202637A | 100 g 1 kg | $60.00 $195.00 | 1 | |
Inhibits poliovirus replication by affecting the viral polymerase, thereby hindering viral RNA synthesis. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
An antiviral agent in research used to for various RNA virus infections; it can interfere with RNA replication, potentially inhibiting Poliovirus Type 3. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
While typically used as an antimalarial, Chloroquine has been observed to have broad antiviral effects, potentially disrupting endosome-mediated viral entry or altering the pH required for viral replication. | ||||||
5-Methoxy-2-methylbenzselenazole | 2946-17-0 | sc-233389 | 5 g | $134.00 | ||
A compound that has shown potential in inhibiting RNA viruses, potentially applicable to Poliovirus Type 3 by interfering with viral RNA synthesis or replication. | ||||||